Feng Ren
CO-CEO, Chief Scientific Officer, Longevity Board Member & Executive DirectorDr. Feng Ren, Ph.D., is Co-Chief Executive Officer at InSilico Medicine Cayman TopCo since June 2022 and is its Chief Scientific Officer since February 2021 & Executive Director since June 2023 and served as its Director since June 2021 until June 2023 and is its Longevity Board Member from April 2026. Dr. Ren joined the InSilico Medicine Cayman TopCo in February 2021. Dr. Ren is Co-CEO, Chief Scientific Officer & Executive Director of Insilico Medicine, Inc. Dr. Ren He served as Senior Vice President and Head of Chemistry and Biology at Shanghai Medicilon Inc. until 2021. He served in various drug discovery leadership roles at GlaxoSmithKline (GSK) in both Philadelphia and Shanghai. Dr. Ren joined Medicilon as Vice President and Head of Chemistry and Biology at Shanghai Medicilon Inc. in February 2018. Before joining Medicilon, He served as the chief researcher, program leader, director and head of chemistry of Neurodegeneration DPU. Dr. Mr. Ren received his bachelor’s degree in polymer science from the University of Science and Technology of China in July 1998, a master’s degree in science in Chemistry from the National University of Singapore in March 2004 and a Ph.D. in organic chemistry from Harvard University in the United States in June 2007.
Positions
- Company NameInSilico Medicine Cayman TopCoStock Code03696PositionCO-CEO, Chief Scientific Officer, Longevity Board Member & Executive DirectorColleagues
- AZAleksandrs ZhavoronkovFounder, CEO, Chief Business Officer, Longevity Board Member & Chairman of the Board
- PDPeng DaiVP & Head of Finance
- AAAleksandr AliperPresident
- XDXiao DingHead of Chemistry
- JWJingsong WangIndependent Non-Executive Director
- RKRoman KyrychynskyiIndependent Non-Executive Director
- AAAndrew AdamsChairman of Longevity Board
